HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $22 Price Target

HC Wainwright & Co. analyst Sara Nik has reiterated a 'Buy' rating on Moleculin Biotech (NASDAQ: MBRX) and maintained a price target of $22 for the stock.